Welcome to our dedicated page for Baudax Bio news (Ticker: BXRX), a resource for investors and traders seeking the latest updates and insights on Baudax Bio stock.
Baudax Bio, Inc. (NASDAQ: BXRX) is a specialized pharmaceutical company focused on developing and commercializing innovative products designed to meet the needs of hospital and acute care settings. The company's lead product candidate is an intravenous form of meloxicam, a non-opioid analgesic that has completed Phase III clinical trials for the management of moderate to severe pain. Current research includes Phase IIIB clinical trials aiming to assess opioid consumption, pain intensity, and the length of hospital stay in colorectal and orthopedic surgery patients. These trials also evaluate various pharmacoeconomic parameters.
Beyond meloxicam, Baudax Bio is advancing a pipeline of early-stage product candidates including RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) in Phase I clinical trials, and RP2000, an ultra-short-acting NMBA currently in pre-clinical trials. The company is also developing a reversal agent for these NMBAs and DEX-IN, a proprietary intranasal formulation of dexmedetomidine.
Recently, Baudax Bio announced that the U.S. FDA has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is a next-generation Treg therapy designed to address Hemophilia A patients with FVIII inhibitors effectively.
Founded in 2019 and based in Malvern, Pennsylvania, Baudax Bio continues to push forward with its mission to develop meaningful therapeutic solutions for acute care settings, drawing on robust clinical research and innovative therapeutic approaches.
Baudax Bio (NASDAQ:BXRX) announces that its President and CEO, Gerri Henwood, will present a corporate overview at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 a.m. ET on Baudax's website, remaining accessible for 30 days post-event. Baudax Bio, focused on therapeutics for acute care, launched its first product, ANJESO, in June 2020 after FDA approval. ANJESO is a once-daily IV NSAID for managing moderate to severe pain.
Baudax Bio (NASDAQ:BXRX) has announced a definitive agreement for a registered direct offering with a healthcare-focused institutional investor, totaling approximately 10.3 million shares at $1.165 each. The offering, expected to close on December 21, 2020, is projected to generate gross proceeds of about $12 million. If all warrants are exercised, an additional $12.15 million may be raised. Funds are intended for commercialization of ANJESO®, pipeline development, and general corporate purposes.
MALVERN, Pa., Nov. 30, 2020 - Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. Institutional investor meetings are scheduled for December 2, 2020, with requests facilitated through Piper Sandler. A pre-recorded fireside chat featuring Henwood is available on the conference site and Baudax Bio's website for 30 days. Baudax Bio focuses on therapeutics for acute care, with its first product, ANJESO, launched in June 2020, following FDA approval in February 2020.
Baudax Bio, Inc. (NASDAQ:BXRX) has announced a definitive agreement with a healthcare-focused investor to sell 10,126,583 shares of common stock and warrants at $1.185 per share, raising approximately $12 million. The offering is a registered direct sale under Nasdaq rules, expected to close around November 25, 2020, pending customary conditions. If warrants are fully exercised, an additional $12.15 million is anticipated. Proceeds will support commercialization of ANJESO®, pipeline development, and general corporate purposes.
ANJESO (meloxicam), launched by Baudax Bio (NASDAQ:BXRX), has been shown to provide superior pain relief compared to other IV non-opioid analgesics. A recent Network Meta-Analysis published in BMC Anesthesiology evaluated over 2,300 studies, concluding that ANJESO significantly reduces pain in post-operative settings within 15 minutes and lasts up to 24 hours. The analysis highlights ANJESO's effectiveness in reducing morphine consumption and its favorable safety profile, making it a viable option for managing moderate to severe pain. ANJESO is FDA-approved and was launched in the U.S. in June 2020.
Baudax Bio, Inc. (NASDAQ:BXRX) announced the issuance of United States Patent No. 10,709,713, covering the use of ANJESO® for treating moderate to severe pain. This patent, which expires in May 2030, strengthens Baudax's position against generic competition. ANJESO, launched in June 2020, is a non-opioid analgesic that addresses significant issues related to opioid use. The patent is part of a broader portfolio aimed at maintaining exclusivity and supporting the commercialization of ANJESO and additional pipeline products.
Baudax Bio (NASDAQ:BXRX) reported significant achievements following the launch of ANJESO®. Over 50 institutions have adopted it into their formularies, and average monthly orders have surged by over 125% since launch. A permanent J-code for ANJESO was secured from CMS effective October 1, enhancing reimbursement processes. Despite positive feedback, the launch revenue ramp is anticipated to take longer due to COVID-19 impacts, which have reduced elective surgeries. The company anticipates maintaining growth in hospital formulary adoption and further integration into pain management protocols.
Baudax Bio (NASDAQ:BXRX) will announce its third quarter 2020 financial results on November 9, 2020, followed by a conference call at 9:00 a.m. ET. The company focuses on therapeutics for acute care, having launched its first product, ANJESO®, in June 2020 after FDA approval in February. ANJESO is an IV NSAID shown effective in managing moderate to severe pain through multiple completed Phase III trials. The company also has other products in development, including novel neuromuscular blocking agents and intranasal dexmedetomidine.
Baudax Bio (NASDAQ:BXRX) announced a successful launch of ANJESO, a non-opioid IV NSAID for managing moderate to severe pain. Over 50 institutions have added ANJESO to their formularies, with a 75% increase in average order size since launch. Despite robust early adoption, the COVID-19 pandemic continues to affect commercial rollout and access to formularies. The company has also executed a warrant exchange to simplify its capital structure, reducing potential shareholder dilution by over 25%.
On October 2, 2020, Baudax Bio (Nasdaq: BXRX) announced the approval of inducement grants by its Compensation Committee. The equity awards include stock options for 24,000 shares and restricted stock units covering 6,000 shares, granted to three new employees as part of their compensation package. The options have an exercise price of $2.77 and a ten-year term, vesting over four years. Baudax Bio focuses on acute care therapeutics, having launched its first product, ANJESO®, in June 2020, approved for managing moderate to severe pain.
FAQ
What is the market cap of Baudax Bio (BXRX)?
What is the primary focus of Baudax Bio, Inc.?
What is Baudax Bio's lead product candidate?
What other products are in Baudax Bio's pipeline?
What recent regulatory milestone has Baudax Bio achieved?
Where is Baudax Bio headquartered?
When was Baudax Bio incorporated?
What is the status of meloxicam's clinical trials?
What is TI-168?
Who can I contact for investor relations information?
Are there any other clinical trials Baudax Bio is involved in?
